B-intervention	0	12	Chemotherapy
I-intervention	13	14	(
I-intervention	14	16	CT
I-intervention	16	17	)
O	18	21	and
B-control	22	36	hormonotherapy
I-control	37	38	(
I-control	38	40	HT
I-control	40	41	)
O	42	44	as
O	45	56	neoadjuvant
O	57	66	treatment
O	67	69	in
B-eligibility	70	77	luminal
I-eligibility	78	84	breast
I-eligibility	85	91	cancer
I-eligibility	92	100	patients
O	100	101	:
O	102	109	results
O	110	114	from
O	115	118	the
O	119	125	GEICAM
O	125	126	/
O	126	130	2006
O	130	131	-
O	131	133	03
O	133	134	,
O	135	136	a
O	137	148	multicenter
O	148	149	,
O	150	160	randomized
O	160	161	,
O	162	167	phase
O	167	168	-
O	168	170	II
O	171	176	study
O	176	177	.

O	178	185	Luminal
O	186	192	breast
O	193	199	cancer
O	200	202	is
O	203	204	a
O	205	211	highly
O	212	221	endocrine
O	222	232	responsive
O	233	240	disease
O	240	241	.

O	242	249	However
O	249	250	,
O	251	254	the
O	255	266	therapeutic
O	267	274	benefit
O	275	277	of
O	278	290	chemotherapy
O	291	292	(
O	292	294	CT
O	294	295	)
O	296	298	in
O	299	303	this
O	304	314	population
O	315	317	is
O	318	321	not
O	322	327	fully
O	328	341	characterized
O	341	342	.

O	343	347	This
O	348	353	study
O	354	366	investigates
O	367	370	the
O	371	376	value
O	377	379	of
O	380	382	CT
O	383	386	and
O	387	394	hormone
O	395	402	therapy
O	403	404	(
O	404	406	HT
O	406	407	)
O	408	410	in
O	411	418	luminal
O	419	425	breast
O	426	432	cancer
O	433	441	patients
O	442	444	in
O	445	448	the
O	449	460	neoadjuvant
O	461	468	setting
O	468	469	.

O	470	478	Patients
O	479	483	with
O	484	492	operable
O	493	499	breast
O	500	506	cancer
O	507	510	and
O	511	531	immunophenotypically
O	532	539	defined
O	540	547	luminal
O	548	555	disease
O	556	557	(
O	557	559	ER
O	559	560	+
O	560	561	/
O	561	563	PR
O	563	564	+
O	564	565	/
O	565	569	HER2
O	569	570	-
O	570	571	/
O	571	582	cytokeratin
O	583	584	8
O	584	585	/
O	585	587	18
O	587	588	+
O	588	589	)
O	590	594	were
O	595	604	recruited
O	604	605	.

O	606	614	Patients
O	615	619	were
O	620	630	randomized
O	631	633	to
O	634	636	CT
O	637	638	(
O	638	648	epirubicin
O	649	651	90
O	652	654	mg
O	654	655	/
O	655	656	m
O	656	657	(
O	657	658	2
O	658	659	)
O	660	664	plus
O	665	681	cyclophosphamide
O	682	685	600
O	686	688	mg
O	688	689	/
O	689	690	m
O	690	691	(
O	691	692	2
O	692	693	)
O	694	695	4
O	696	702	cycles
O	703	711	followed
O	712	714	by
O	715	724	docetaxel
O	725	728	100
O	729	731	mg
O	731	732	/
O	732	733	m
O	733	734	(
O	734	735	2
O	736	737	)
O	737	738	4
O	739	745	cycles
O	746	747	[
O	747	749	EC
O	749	750	-
O	750	751	T
O	751	752	]
O	752	753	)
O	754	756	or
O	757	759	HT
O	760	761	(
O	761	771	exemestane
O	772	774	25
O	775	777	mg
O	778	783	daily
O	784	786	24
O	787	792	weeks
O	793	794	[
O	794	802	combined
O	803	807	with
O	808	817	goserelin
O	818	820	in
O	821	834	premenopausal
O	835	843	patients
O	843	844	]
O	844	845	)
O	845	846	.

O	847	850	The
O	851	858	primary
O	859	862	end
O	863	868	point
O	869	872	was
O	873	876	the
B-outcome-Measure	877	885	clinical
I-outcome-Measure	886	894	response
O	895	903	measured
O	904	906	by
O	907	915	magnetic
O	916	925	resonance
O	926	933	imaging
O	933	934	.

B-total-participants	935	941	Ninety
I-total-participants	941	942	-
I-total-participants	942	946	five
O	947	955	patients
O	956	960	were
O	961	971	randomized
O	972	973	(
B-intervention-participants	973	975	47
O	976	978	CT
O	978	979	,
B-control-participants	980	982	48
O	983	985	HT
O	985	986	)
O	986	987	.

O	988	991	The
B-outcome	992	1000	clinical
I-outcome	1001	1009	response
I-outcome	1010	1014	rate
O	1015	1018	was
B-iv-bin-percent	1019	1021	66
I-iv-bin-percent	1021	1022	%
O	1023	1026	for
O	1027	1029	CT
O	1030	1033	and
B-cv-bin-percent	1034	1036	48
I-cv-bin-percent	1036	1037	%
O	1038	1041	for
O	1042	1044	HT
O	1045	1046	(
O	1046	1047	P
O	1048	1049	=
O	1050	1051	0
O	1051	1052	.
O	1052	1055	075
O	1055	1056	)
O	1056	1057	.

O	1058	1060	We
O	1061	1070	performed
O	1071	1073	an
O	1074	1083	unplanned
O	1084	1092	analysis
O	1093	1098	based
O	1099	1101	on
O	1102	1106	Ki67
O	1107	1113	levels
O	1114	1115	(
O	1115	1118	cut
O	1118	1119	-
O	1119	1122	off
O	1123	1125	of
O	1126	1128	10
O	1128	1129	%
O	1129	1130	)
O	1130	1131	.

O	1132	1139	Similar
B-outcome	1140	1148	clinical
I-outcome	1149	1157	response
O	1158	1161	was
O	1162	1166	seen
O	1167	1174	between
O	1175	1179	arms
O	1180	1182	in
B-outcome	1183	1191	patients
I-outcome	1192	1196	with
I-outcome	1197	1200	low
I-outcome	1201	1205	Ki67
O	1206	1207	(
O	1207	1209	CT
O	1209	1210	:
B-iv-bin-percent	1211	1213	63
I-iv-bin-percent	1213	1214	%
O	1214	1215	,
O	1216	1218	HT
O	1218	1219	:
B-cv-bin-percent	1220	1222	58
I-cv-bin-percent	1222	1223	%
O	1223	1224	;
O	1225	1226	P
O	1227	1228	=
O	1229	1230	0
O	1230	1231	.
O	1231	1233	74
O	1233	1234	)
O	1234	1235	;
B-outcome	1236	1244	patients
I-outcome	1245	1249	with
I-outcome	1250	1254	high
I-outcome	1255	1259	Ki67
O	1260	1263	had
O	1264	1265	a
O	1266	1272	better
O	1273	1281	response
O	1282	1286	with
O	1287	1289	CT
O	1290	1291	(
B-iv-bin-percent	1291	1293	67
O	1294	1300	versus
B-cv-bin-percent	1301	1303	42
I-cv-bin-percent	1303	1304	%
O	1304	1305	;
O	1306	1307	P
O	1308	1309	=
O	1310	1311	0
O	1311	1312	.
O	1312	1315	075
O	1315	1316	)
O	1316	1317	.

B-outcome	1318	1323	Grade
I-outcome	1324	1325	3
I-outcome	1325	1326	/
I-outcome	1326	1327	4
I-outcome	1328	1336	toxicity
O	1337	1340	was
O	1341	1345	more
O	1346	1354	frequent
O	1355	1359	with
O	1360	1362	CT
O	1362	1363	.

O	1364	1371	Luminal
O	1372	1387	immunophenotype
O	1388	1390	is
O	1391	1394	not
O	1395	1401	enough
O	1402	1404	to
O	1405	1413	identify
O	1414	1422	patients
O	1423	1426	who
O	1427	1429	do
O	1430	1433	not
O	1434	1441	benefit
O	1442	1446	from
O	1447	1458	neoadjuvant
O	1459	1461	CT
O	1461	1462	.

O	1463	1470	Luminal
O	1471	1479	patients
O	1480	1484	with
O	1485	1488	low
O	1489	1502	proliferation
O	1503	1508	index
O	1509	1514	could
O	1515	1526	potentially
O	1527	1532	avoid
O	1533	1535	CT
O	1535	1536	.
